A new name, an old crisis: Metabolic dysfunction at the core of polyendocrine metabolic ovarian syndrome.

Renaming polyendocrine metabolic ovarian syndrome highlights its core metabolic dysfunction, emphasizing its link to increased cardiovascular and metabolic disease risks in millions of women.

• Why it matters: Understanding and addressing this condition is crucial because it is widely misunderstood and lacks sufficient basic metabolic research funding, hindering effective treatment development.
• What they did: The authors analyze the implications of renaming the syndrome from polycystic ovary syndrome to PMOS, aiming to reframe its metabolic roots and improve research focus.
• The result: This redefinition could lead to better recognition of the disease’s metabolic basis, fostering targeted research efforts and improved health outcomes for affected women.